Francesca Fontana

This one data point I found really highlights just how massive these deals are.

Apparently, the total scale of computing capacity that OpenAI's agreed to buy is now 26 gigawatts.

That's enough power to meet the summer electricity needs of New York City more than two times over.

Broadcom shares jumped 9.9% on Monday and held on to most of those gains throughout the week.

And here's another chat GPT headline from this week.

Walmart will soon be selling its products right within the AI chatbot.

The retail giant's partnership with OpenAI will let U.S.-based users purchase nearly everything that they could get from the Walmart website, except for fresh food.

And Walmart shares ended up gaining 5% on Tuesday and on a weekly basis rose 5.8%.

Next up, let's look at some health-related stocks making moves this week.

Hims and Hers shares jumped 16% on Wednesday on the news that the telehealth company will now offer menopause and perimenopause care.

Hims and Hers said it expects the new specialty to help Hers, its women's health unit, to surpass $1 billion in annual revenue next year.

Now let's jump to Friday's session.

Pharma stocks Novo Nordisk and Eli Lilly really needed a shot in the arm after comments from President Trump the day before sent their shares falling.

While speaking in the Oval Office, Trump said that the out-of-pocket cost of Ozempic could fall to $150.

For reference, Ozempic currently has a U.S.

list price of nearly $1,000 a month.

Now remember, Novo Nordisk makes Ozempic, as well as another weight loss drug, Wagovi.

And Eli Lilly sells similar drugs, Monjaro and Zepbound.

Now, these drugs costs are still apparently being negotiated, so this is just talk, so to speak.

But the pricing concerns were enough to send U.S.-traded shares of Novo Nordisk down 3.1% on Friday, losing 4.5% for the week.